Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001213900-24-095398
Filing Date
2024-11-07
Accepted
2024-11-07 16:05:51
Documents
55
Period of Report
2024-09-30

Document Format Files

Seq Description Document Type Size
1 QUARTERLY REPORT ea0217510-10q_relmada.htm   iXBRL 10-Q 476094
2 CERTIFICATION ea021751001ex31-1_relmada.htm EX-31.1 11297
3 CERTIFICATION ea021751001ex31-2_relmada.htm EX-31.2 11127
4 CERTIFICATION ea021751001ex32-1_relmada.htm EX-32.1 4417
5 CERTIFICATION ea021751001ex32-2_relmada.htm EX-32.2 4453
  Complete submission text file 0001213900-24-095398.txt   3482889

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE rlmd-20240930.xsd EX-101.SCH 31676
7 XBRL CALCULATION FILE rlmd-20240930_cal.xml EX-101.CAL 22834
8 XBRL DEFINITION FILE rlmd-20240930_def.xml EX-101.DEF 174868
9 XBRL LABEL FILE rlmd-20240930_lab.xml EX-101.LAB 332119
10 XBRL PRESENTATION FILE rlmd-20240930_pre.xml EX-101.PRE 184497
58 EXTRACTED XBRL INSTANCE DOCUMENT ea0217510-10q_relmada_htm.xml XML 284426
Mailing Address 2222 PONCE DE LEON BLVD. 3RD FLOOR CORAL GABLES FL 33134
Business Address 2222 PONCE DE LEON BLVD. 3RD FLOOR CORAL GABLES FL 33134 646 876 3459
RELMADA THERAPEUTICS, INC. (Filer) CIK: 0001553643 (see all company filings)

EIN.: 455401931 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39082 | Film No.: 241435546
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)